Pharma Foods International Co., Ltd. (JP:2929) has released an update.
Pharma Foods International Co., Ltd. (PFI) has reached a significant milestone under its Exclusive Licensing Agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) for a new antibody aimed at treating autoimmune diseases. The antibody, developed using PFI’s proprietary ALAgene® technology, is set to enter Phase I clinical trials following the acceptance of an initial Clinical Trial Notification. PFI’s achievement paves the way for a milestone payment and reinforces its commitment to addressing unmet medical needs.
For further insights into JP:2929 stock, check out TipRanks’ Stock Analysis page.
